^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
YTS105
i
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
BriSTAR Immunotech, Peking University
Drug class:
Mesothelin-targeted CAR-T immunotherapy
Related drugs:
Phase 1
Peking University
Not yet recruiting
Last update posted :
04/25/2022
Initiation :
04/14/2022
Primary completion :
10/14/2024
Completion :
02/01/2026
EGFR • ALK • MET • ROS1 • MSLN
|
ALK positive • EGFR positive • EGFR negative • MSLN positive
|
YTS105
Share
